D. Western Therapeutics Institute, Inc.
Notice on Monthly Exercise Status of Series 14 Stock Acquisition Rights (with Exercise Price Adjustment Provision)
Published the monthly exercise status for Series 14 stock acquisition rights for October 2026. Number of shares granted: 1,085,300 shares; number of options exercised: 10,853 units; exercise rate: 2.78%; unexercised shares: 390,000 shares (end of previous month) and 379,147 shares (end of month).
Key Figures
- Number of shares granted: 1,085,300 shares
- Number of stock acquisition rights exercised: 10,853 units
- New shares: 178–1,434 shares (by applicable date)
- Total issued: 57,599,412 shares
- Number of unexercised shares: 390,000 shares (end of previous month) / 379,147 shares (end of month)
- Exercise ratio: 1.88% (ratio based on exercise restrictions as of end of previous month)
AI要約
Overview
This disclosure reports the monthly exercise status of the Series 14 stock acquisition rights (with exercise price adjustment provision). For the subject month, the number of shares granted was 1,085,300 shares, the number of stock acquisition rights actually exercised was 10,853 units, and the newly issued shares after transfer were observed in a distribution of 178 to 1,434 shares. The exercise ratio against the total issued is 2.78%, and unexercised rights stood at 390,000 shares at the end of the previous month and 379,147 shares at the end of the month.
Impact on Shareholders and Outlook
Given the low exercise rate, short-term dilution effects are considered limited. It is necessary to monitor exercise trends and the movement of unexercised rights through future monthly disclosures. For details on past announcement dates, refer to the notice published on September 14, 2026.
D. Western Therapeutics Institute, Inc.
Company overview · Stock price · Financial data · All IR
